物质信息
ID:1169
名称和标识
别名
Cefoperazono [inn-spanish]Cefoperazonum [inn-latin]Cefoperazone
IUPAC传统名
(6R,7R)-7-[2-(4-ethyl-2,3-dioxopiperazine-1-carbonylamino)-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
商标名
Cefobid
IUPAC标准名
(6R,7R)-7-{2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-(4-hydroxyphenyl)acetamido}-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
化合物性质
理化性质
疏水性(logP)
-0.74 [HANSCH,C ET AL. (1995)]
描述信息
Drug Groups
approved
Description
Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It has been proposed especially against Pseudomonas infections.
Indication
For the treatment of bacterial infections caused by susceptible microorganisms.
Pharmacology
Cefoperazone is a third generation cephalosporin antibiotic. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis
Toxicity
Symptoms of overdose include blood in the urine, diarrhea, nausea, upper abdominal pain, and vomiting.
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation
No significant quanitity of metabolites have been identified in urine.
Half Life
The mean serum half-life is approximately 2.0 hours, independent of the route of administration.
Protein Binding
The degree of reversible protein binding varies with the serum concentration from 93% at 25 mcg/mL to 90% at 250 mcg/mL and 82% at 500 mcg/mL. Cefotetan is 88% plasma protein bound.
Elimination
Cefoperazone is excreted mainly in the bile.
References
•
Jones RN, Barry AL: Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S108-26.
[Pubmed]
External Links
分子图谱
暂无数据
点击上传数据
参考文献
• Jones RN, Barry AL: Cefoperazone: a review of its antimicrobial spectrum, beta-lactamase stability, enzyme inhibition, and other in vitro characteristics. Rev Infect Dis. 1983 Mar-Apr;5 Suppl 1:S108-26. Pubmed